Apr 13, 2021 (StockMarket.com via COMTEX) -- Are These Best Health Care Stocks To Buy In The Stock Market Today?
Health care is something that everyone needs at some point in their lives. Therefore, there are always opportunities for investors in health care stocks . It doesn't take a genius to guess that the sector is home to some of the best-performing stocks in the stock market throughout the pandemic. With new scientific innovations, continuous investment into research and development, and a resurging global economy, the health care sector continues to bring rewards to investors.
For instance, we have biotech companies such as Novavax ( NASDAQ: NVAX ) which gained support from GlaxoSmithKline ( NYSE: GSK ) to manufacture up to 60 million doses of the COVID-19 vaccine in March. Also, there's Rubius Therapeutics ( NASDAQ: RUBY ) which deals with cancer treatment and autoimmune diseases. Both companies performed exceptionally well over the past year. On one hand, Novavax multiplied in value by almost tenfold. On the other, Rubius Therapeutics quadrupled in value over the past year. Health care stocks are getting a lot of attention these days, thanks in large part to the global pandemic. On top of that, health care is relatively recession-proof. Patients that require treatment will spend on treatment even if it means cutting back on discretionary items. With all that said, do you have these top health care stocks on your watchlist?
Best Health Care Stocks To Watch Right Now
Moderna Inc ( NASDAQ: MRNA )
Celcuity Inc ( NASDAQ: CELC )
Taysha Gene Therapies Inc ( NASDAQ: TSHA )
Regeneron Pharmaceuticals Inc ( NASDAQ: REGN )
Moderna is an mRNA vaccine company that has been one of the biggest winners in the healthcare sector. The company is one of the first in the world to receive the Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its coronavirus vaccine. In addition, its mRNA science is also contributing to the development of new drugs in the foreseeable future. For example, Moderna is developing therapeutics for infectious diseases, immuno-oncology, and cardiovascular diseases.
On Monday, contract drugmaker Rovi revealed that it will be making active ingredients for Moderna's COVID-19 vaccine, extending an existing agreement to bottle the vaccine. Moderna has said it will make at least 700 million doses of vaccine in 2021, including from plants in Europe and the United States. The company is not resting on its laurels and is actively expanding its operations to battle the global pandemic. On the note of countries accepting its vaccines, the United Kingdom has become the latest country to roll out Moderna's vaccines last week.
Furthermore, the company also highlighted the publication of antibody persistence data out of 6 months following the second dose of the Moderna COVID-19 vaccine. This gives the company and investors confidence in the protection provided by its vaccines. Hence, with so many developments around the company, would you buy MRNA stock?
[Read More] Best Stocks To Buy Now? 4 Tech Stocks to Watch
Celcuity is a clinical-stage biotech company with the goals of extending the lives of cancer patients. It aims to achieve this by pursuing an integrated companion diagnostic (CDx) and therapeutic strategy. In detail, Celcuity's CELsignia diagnostic platform analyzes live patient tumor cells to identify new groups of cancer patients likely to benefit from targeted therapies. With this strategy, the company is driven to help patients receive the drugs best able to extend their lives. For those who are on the lookout for the next big thing in health care, this could be worth looking at. Celcuity's shares surged by 29% on Monday after its latest deal.
In detail, the company struck a licensing deal with Pfizer ( NYSE: PFE ) for a breast cancer treatment candidate. This allows Celcuity exclusive rights to the drug known as gedatolisib. The drug has shown promise in 103 patients in early-stage testing, Celcuity said in a news release. Gedatolisib is being tested as a treatment for patients whose breast cancer is tied to estrogen receptors. That covers about 70%-80% of breast cancers in the U.S. Could this deal be the precursor to bigger things to come with Celcuity? If you believe so, do you think CELC stock has a long runway ahead?